Liraglutide Reduced MACE in Patients With Type 2 Diabetes at High CV Risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Cardiology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial
JAMA Cardiol 2019 Nov 13;[EPub Ahead of Print], S Verma, SC Bain, JB Buse, T Idorn, S Rasmussen, DD Ørsted, MA NauckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.